Trieu Vuong's Form 4 filing
Oncotelic Therapeutics, Inc. (OTLC) · filed Jun 17, 2026
- Accession no.
- 0001493152-26-029137
- Filed
- Jun 17, 2026, 7:34 PM ET
- Trade date
- Jun 15-17, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $15.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Trieu VuongCIK 0001587074 | Director, Officer (CHAIRMAN AND CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Common Stock | PPurchaseAcquired | +239,759 | $0.0446 | +$10,693.25 | 93,629,319 | Direct | |
| Jun 15, 2026 | Common Stock | PPurchaseAcquired | +96,000 | $0.045 | +$4,320 | 93,389,560 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.